PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration

A large proportion of patients with chronic myeloid leukemia (CML; 20%–50%) develop resistance to imatinib in a BCR-ABL1-independent manner. Therefore, new therapeutic strategies for use in this subset of imatinib-resistant CML patients are urgently needed. In this study, we used a multi-omics appro...

Cijeli opis

Bibliografski detalji

Glavni autori:	Rui Su, Chuting Li, Xiuyuan Wang, Zhendong Li, Ziqi Wen, Zhao Yin, Guiping Huang, Yanjun Liu, Juhua Yang, Haiyan Hu, Hong Nie, Keda Zhang, Jia Fei
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2023-06-01
Serija:	Molecular Therapy: Nucleic Acids
Teme:	MT: Non-coding RNAs chronic myeloid leukemia BCR-ABL1-independent imatinib resistance drug resistance small activating RNA (saRNA) mir-181a
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2162253123001129
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!